Eli Lilly targets Scorpion Therapeutics to expand reach in oncology
Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away…
Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away…
President-elect Donald Trump has appointed Robert F Kennedy Jr, popularly known as RFK Jr, as the secretary of the premier…
After trialling a subscription-style system for procuring antimicrobial drugs, the UK’s National Health Service recently announced that it will formalise…
The ongoing European Union (EU) elections, a revision of key legislation governing the pharmaceutical and biotech industry in Europe, and…
Tackling two of the buzziest trends in pharma right now; AI and mRNA therapeutics, is high on the agenda of…
An upcoming session designed to gather suggestions to optimise the US Food and Drug Administration (FDA) Advisory Committee (AdCom) meetings…
The last year was a momentous one for RSV research with more than one vaccine and a new treatment for…
As the number of specialised gene therapies continues to grow in the biotech sector, one particular subtype— those using adeno-associated…
In the last few years, multimillion dollar revenues driven by popular demand, and even higher projections for the future have…
Running a successful clinical trial requires a combination of sector expertise, an eye towards emerging technologies and efforts to consider…